Trial record 2 of 192 for:
Transient Ischemic Attack
Pilot Study of Continuing Aspirin Versus Switching to Clopidogrel After Stroke or Transient Ischemic Attack
This study has been withdrawn prior to enrollment.
Sponsor:
University of California, San Diego
Information provided by:
University of California, San Diego
ClinicalTrials.gov Identifier:
NCT00363753
First received: August 10, 2006
Last updated: March 30, 2007
Last verified: March 2007
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Pilot study of continuing aspirin versus switching to clopidogrel after stroke or transient ischemic attack.
| Condition | Intervention | Phase |
|---|---|---|
|
Transient Ischemic Attack Stroke Aspirin Clopidogrel |
Drug: aspirin versus clopidogrel |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Pilot Study of Continuing Aspirin Versus Switching to Clopidogrel After Stroke or Transient Ischemic Attack |
Resource links provided by NLM:
Further study details as provided by University of California, San Diego:
Primary Outcome Measures:
- mRS at three months.
Secondary Outcome Measures:
- Incidence of stroke at three months, bleeding events.
| Estimated Enrollment: | 20 |
| Study Start Date: | August 2006 |
| Estimated Study Completion Date: | March 2007 |
Pilot study of continuing aspirin versus switching to clopidogrel after stroke or transient ischemic attack.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age 18 and older.
- Stroke or transient ischemic attack (TIA) while taking aspirin within one week of consent.
- Women of child-bearing potential will be included only if there is a negative pregnancy test and they agree to birth control during the treatment period.
Exclusion Criteria:
- Any medical indication for a specific antiplatelet agent (aspirin, clopidogrel, ticlopidine, aggrenox), or an indication for a combination of antiplatelet agents.
- Any medical indication for anticoagulation, except subcutaneous heparin for deep vein thrombosis prophylaxis.
- Allergy to aspirin or clopidogrel.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00363753
Locations
| United States, California | |
| UCSD Hillcrest | |
| San Diego, California, United States, 92103 | |
| UCSD | |
| San Diego, California, United States, 92103 | |
Sponsors and Collaborators
University of California, San Diego
Investigators
| Principal Investigator: | Matt B Jensen, MD | UCSD Stroke Center |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00363753 History of Changes |
| Other Study ID Numbers: | UCSD IRB #060452 |
| Study First Received: | August 10, 2006 |
| Last Updated: | March 30, 2007 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of California, San Diego:
|
Transient ischemic attack Stroke Aspirin Clopidogrel |
Additional relevant MeSH terms:
|
Ischemic Attack, Transient Ischemia Brain Ischemia Stroke Cerebral Infarction Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases Pathologic Processes Brain Infarction Aspirin Clopidogrel |
Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Anti-Inflammatory Agents Therapeutic Uses Antirheumatic Agents Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Cardiovascular Agents Hematologic Agents |
ClinicalTrials.gov processed this record on May 19, 2013